busol stungulyf, lausn 0,004 mg/ml
t.p. whelehan son & co. ltd. - buserelinum acetat - stungulyf, lausn - 0,004 mg/ml
astrozol filmuhúðuð tafla 1 mg
williams & halls ehf - anastrozolum inn - filmuhúðuð tafla - 1 mg
anastrozole alvogen (anastrozole teva) filmuhúðuð tafla 1 mg
alvogen ehf. - anastrozolum inn - filmuhúðuð tafla - 1 mg
bicalutamide alvogen (bicalutamide portfarma) filmuhúðuð tafla 50 mg
alvogen ehf. - bicalutamidum inn - filmuhúðuð tafla - 50 mg
reseligo (goserelin alvogen) vefjalyf í áfylltri sprautu 10,8 mg
zentiva k.s.* - goserelinum acetat - vefjalyf í áfylltri sprautu - 10,8 mg
reseligo (goserelin alvogen) vefjalyf í áfylltri sprautu 3,6 mg
alvogen ehf. - goserelinum acetat - vefjalyf í áfylltri sprautu - 3,6 mg
zoladex vefjalyf 10,8 mg
astrazeneca ab - goserelinum acetat - vefjalyf - 10,8 mg
zoladex vefjalyf 3,6 mg
astrazeneca ab - goserelinum acetat - vefjalyf - 3,6 mg
firmagon
ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - blöðruhálskirtli - innkirtla meðferð - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.